Spinocerebellar Ataxia Type 3 (SCA3) neurons represent a specific neuronal population affected in Machado-Joseph disease (MJD), the most common dominant ataxia worldwide. These neurons harbor the pathogenic polyglutamine expansion in the ATXN3 gene and demonstrate characteristic degeneration primarily affecting cerebellar outflow pathways, brainstem nuclei, and spinal cord neurons.
| Property |
Value |
| Category |
Neurodegeneration-associated neurons |
| Gene |
ATXN3 (Ataxin-3) |
| Mutation |
CAG repeat expansion (polyglutamine) |
| Normal Repeat |
12-44 CAG repeats |
| Pathogenic Repeat |
52-86+ CAG repeats |
| Protein |
Ataxin-3 ( Machado-Joseph disease protein) |
| Brain Regions Affected |
Cerebellar dentate nucleus, brainstem, spinal cord |
¶ ATXN3 Gene and Protein
The ATXN3 gene (also known as MJD1) is located on chromosome 14q32.12 and encodes the ataxin-3 protein, a deubiquitinating enzyme involved in protein quality control:
- Josephin domain: Catalytic deubiquitinase activity
- Polyglutamine (polyQ) tract: Pathogenic expansion causes disease
- UIM (Ubiquitin-interacting motif) domains: Bind polyubiquitin chains
- Nuclear localization signals: Regulate nuclear-cytoplasmic trafficking
The polyglutamine expansion in ataxin-3 leads to:
- Toxic gain-of-function: Mutant protein forms aggregates
- Proteasomal dysfunction: Impaired protein degradation
- Transcriptional dysregulation: Altered gene expression
- Mitochondrial dysfunction: Energy production deficits
- RNA toxicity: Non-coding repeat RNA effects
- Neuronal network dysfunction: Synaptic impairment
¶ Anatomy and Affected Regions
The dentate nucleus is the primary site of pathology:
- Large projection neurons degenerate
- Output to thalamus disrupted
- Motor coordination severely impaired
- Iron accumulation observed in affected neurons
Multiple brainstem nuclei are affected:
- Red nucleus: Rubral tremor development
- Substantia nigra: Parkinsonism features
- Vestibular nuclei: Balance dysfunction
- Cranial nerve nuclei: Dysphagia, dysarthria
- Anterior horn cells: Lower motor neuron involvement
- Spinocerebellar tracts: Sensory ataxia contribution
- Corticospinal tracts: Weakness and spasticity
Ataxin-3 in healthy neurons:
- Protein quality control: Removes polyubiquitin chains
- Transcriptional regulation: Modulates gene expression
- DNA repair: Involved in repair pathways
- Autophagy: Regulates autophagic flux
- Mitochondrial function: Maintains energy homeostasis
Pathological changes include:
- Aggregate formation: Intranuclear inclusions
- Loss of deubiquitinase activity: Impaired protein clearance
- Transcriptional changes: Downregulation of neuronal genes
- Synaptic deficits: Impaired neurotransmission
- Calcium dysregulation: Altered signaling
SCA3/MJD presents with:
-
Ataxia: Progressive cerebellar dysfunction
- Gait instability
- Limb incoordination
- Dysmetria
- Scanning speech
-
Parkinsonism: In some patients
- Bradykinesia
- Rigidity
- Resting tremor
-
Spasticity: Upper motor neuron signs
- Hyperreflexia
- Muscle stiffness
- Babinski sign
-
Peripheral neuropathy: Sensory involvement
- Decreased sensation
- Muscle weakness
- Reduced reflexes
- Ophthalmoplegia: Eye movement abnormalities
- Dystonia: Involuntary movements
- Cognitive impairment: Executive dysfunction (variable)
- Psychiatric symptoms: Depression, anxiety
- Neuronal loss: Severe in affected regions
- Gliosis: Reactive astrocytosis
- Intranuclear inclusions: Polyglutamine aggregates
- Neurofibrillary tangles: Tau pathology (in some cases)
- Iron deposition: In dentate nucleus
- Aggregate formation: Mutant ataxin-3 accumulates
- Ubiquitin accumulation: Impaired degradation
- Oxidative stress: Reactive oxygen species
- Mitochondrial defects: Complex I deficiency
- ER stress: Unfolded protein response
-
Gene silencing
- Antisense oligonucleotides (ASOs)
- RNA interference (RNAi)
- CRISPR-based approaches
-
Protein-targeting therapies
- Aggregation inhibitors
- Deubiquitinase modulators
- Autophagy enhancers
-
Cellular protection
- Neurotrophic factors
- Antioxidants
- Mitochondrial protectors
- Ataxia: Physical therapy, assistive devices
- Spasticity: Baclofen, botulinum toxin
- Parkinsonism: Dopaminergic medications
- Dystonia: Anticholinergics, DBS
- Dysphagia: Swallowing therapy
Multiple clinical trials are investigating:
- ASO therapies (e.g., tonabersat)
- Gene therapy approaches
- Neuroprotective agents
- Symptomatic treatments
- Induced pluripotent stem cells (iPSCs): Patient-derived neurons
- Knock-in mouse models: Pathogenic repeat insertion
- Transgenic models: Mutant ATXN3 expression
- High-throughput screening: Drug candidates
- Biomarker development: Disease progression markers
- Neuroimaging: MRI, PET studies
- Electrophysiology: Biomarker assessment
- Autosomal dominant: One mutant allele sufficient
- Anticipation: Earlier onset in successive generations
- Maternal bias: Possible imprinting effects
- Diagnostic testing: Confirm clinical diagnosis
- Presymptomatic testing: At-risk individuals
- Prenatal testing: Family planning
- Carrier testing: Reproductive counseling
- Kawaguchi Y, et al. Machado-Joseph disease gene product is a nuclear protein. Nat Genet. 1994
- Geschwind DH, et al. Ataxin-3: a neuronal deubiquitinase. Neuron. 1997
- McLoughlin HS, et al. Pathogenesis of SCA3: therapeutic implications. J Mol Neurosci. 2016
- Ross CA, et al. Polyglutamine diseases: molecular biology and pathogenesis. Nat Rev Neurosci. 2013
- Costa Mdo C, et al. Animal models of SCA3. Cerebellum. 2013
- Matos CA, et al. Polyglutamine diseases: the special case of ataxin-3. Prog Neurobiol. 2019
- Paulson HL, et al. Dominant ataxias. Continuum. 2016
- Sakai H, et al. Dentate nucleus pathology in SCA3. J Neurol Sci. 2019
- Matsumura R, et al. Neuropathology of SCA3. Brain Pathol. 1997
- Chen L, et al. Therapeutic strategies for SCA3. Mov Disord. 2019